Novel targeted agents for the treatment of lung cancer in China

Cancer

Volumn 121, Issue S17, 2015, Pages 3089-3096

  Liu, Si Yang ^a   Mok, Tony ^b   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

China; lung cancer; novel agents; novel targets

Indexed keywords

ALECTINIB; ALLITINIB; ANTINEOPLASTIC AGENT; APATINIB; AVITINIB; BEVACIZUMAB; BGL 398; BINIMETINIB; BRIGATINIB; CAPMATINIB; CERITINIB; CRIZOTINIB; CT 053 PTSA; FAMITINIB; FRUQUINTINIB; GEFITINIB; HMPL 813; MAMMALIAN TARGET OF RAPAMYCIN; NINTEDANIB; OSIMERTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VOLITINIB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHINA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGFR GENE; FGFR1 GENE; GENE; GENE AMPLIFICATION; GENE FUSION; GENE MUTATION; HUMAN; MET GENE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROS1 GENE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; MOLECULAR EPIDEMIOLOGY; MUTATION;

CARCINOMA, NON-SMALL-CELL LUNG; CHINA; HUMANS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84940706103     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29522     Document Type: Review

References (58)

1. Mok TS, Wu YL, Thongprasert S, et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
2. Mitsudomi T, Morita S, Yatabe Y, et al,; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11: 121-128.
3. Maemondo M, Inoue A, Kobayashi K, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388.
4. Zhou C, Wu YL, Chen G, et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735-742.
5. Rosell R, Carcereny E, Gervais R, et al,; Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
6. Han JY, Park K, Kim SW, et al., First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30: 1122-1128.
7. Sequist L, Yang JC, Yamamoto N, et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31: 3327-3334.
8. Wu YL, Li CK, Zhou C, et al., First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analysis from the phase 3, open-label, ENSURE study. J Thorac Oncol. 2013; 8 (suppl 2): S603.
9. Wu YL, Zhou C, Hu CP, et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213-222.
10. Camidge DR, Bang YJ, Kwak EL, et al., Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-1019.
11. Kim DW, Ahn MJ, Shi Y, et al., Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012; 30 (suppl 15): 7533.
12. Shaw AT, Kim DW, Nakagawa K, et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385-2394.
13. Solomon BJ, Mok T, Kim DW, et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371: 2167-2177.
14. Kris MG, Johnson BE, Berry LD, et al., Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998-2006.
15. Wu YL, Gou LY,. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China. Lung Cancer Targets Ther. 2014; 5: 1-9.
16. He YY, Zhang XC, Yang JJ, et al., Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer. Clin Lung Cancer. 2014; 15: 441-447.
17. Wu YL, Zhou Q,. Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets. 2012; 16 (suppl 1): S45-S50.
18. Jiang L, Huang J, Morehouse C, et al., Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genet. 2013; 206: 330-339.
19. Zhang X, Zhang S, Yang X, et al., Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010; 9: 188.
20. Reinmuth N, Heigener D, Reck M,. Novel angiogenesis inhibitors in nonsmall cell lung cancer. Curr Opin Oncol. 2015; 27: 79-86.
21. Sandler A, Gray R, Perry MC, et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
22. Reck M, von Pawel J, Zatloukal P, et al., Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009; 27: 1227-1234.
23. Crino L, Dansin E, Garrido P, et al., Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010; 11: 733-740.
24. Zhou C, Wu YL, Chen G, et al., BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer [published online ahead of print May 26, 2015]. J Clin Oncol. pii: JCO.2014.59.4424.
25. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G,. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014; 2: 123.
26. Poole RM, Vaidya A,. Ramucirumab: first global approval. Drugs. 2014; 74: 1047-1058.
27. Nelson R,. FDA approves ramucirumab for non-small sell lung cancer. Available at: www.medscape.com/viewarticle/836523. Accessed December 12, 2014.
28. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M,. A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer. 2012; 13: 505-509.
29. Stinchcombe TE,. Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol. 2014; 6: 240-253.
30. Reck M, Kaiser R, Mellemgaard A, et al., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15: 143-155.
31. Novello S, Kaiser R, Mellemgaard A, et al,; LUME-Lung 1 Study Group. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2015; 51: 317-326.
32. Li J, Qin S, Xu J, et al., Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013; 31: 3219-3225.
33. Li J,. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial [abstract 4003]. Presented in abstract form at: 50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014; May 30-June 3, 2014; Chicago, IL.
34. Cao J, Zhang J, Wang Z, et al., Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer. Cancer Chemother Pharmacol. 2014; 74: 389-398.
35. Sun Q, Zhou J, Zhang Z, et al., Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014; 15: 1635-1645.
36. China Food and Drug Administration. 2010 China Drug Review Annual Report. Beijing, China: China Food and Drug Administration; 2011.
37. Sequist LV, Waltman BA, Dias-Santagata D, et al., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011; 3: 75ra26.
38. Chen HJ, Mok TS, Chen ZH, et al., Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009; 15: 651-658.
39. Lai Y, Zhang Z, Li J, et al., EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci. 2013; 14: 24549-24559.
40. Yang JJ, Chen HJ, Yan HH, et al., Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer. 2013; 79: 33-39.
41. Parums DV,. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc). 2014; 50: 503-525.
42. Li A, Gao HF, Wu YL,. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin Ther Targets. 2015; 19: 663-674.
43. Wu YL, Yang JC, Kim DW, et al., Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase lb/ll study. Presented at: 50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014; May 30-June 3, 2014; Chicago, IL.
44. Camidge DR, Ou S, Shapiro G, et al., Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [abstract 8001]. Presented in abstract form at: 50th American Society of Clinical Oncology (ASCO) Annual Meeting 2014; May 30-June 3, 2014; Chicago, IL.
45. Gavine PR, Ren Y, Han L, et al., Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015; 9: 323-333.
46. Rossi A, Maione P, Sacco PC, et al., ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 2014; 45: 499-508.
47. Shaw AT, Kim DW, Mehra R, et al., Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370: 1189-1197.
48. Gadgeel SM, Gandhi L, Riely GJ, et al., Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014; 15: 1119-1128.
49. Nguyen KS, Neal JW, Wakelee H,. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol. 2014; 5: 576-587.
50. Kim HR, Kim DJ, Kang DR, et al., Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol. 2013; 31: 731-737.
51. Chen YF, Hsieh MS, Wu SG, et al., Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014; 9: 1171-1179.
52. Shaw AT, Ou SH, Bang YJ, et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371: 1963-1971.
53. Chia S, Gandhi S, Joy AA, et al., Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015; 22: 33-48.
54. Zhou Q, Zhang XC, Peng B, et al., A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2014; 32 (suppl 15): TPS8122.
55. China Food and Drug Administration. 2014 China Drug Review Annual Report. Beijing, China: China Food and Drug Administration; 2015.
56. Wu YL, Zhang H, Yang Y,. Cancer drug development in China: recent advances and future challenges [published online ahead of print November 20, 2014]. Drug Discov Today. doi: 10.1016/j.drudis.2014.11.005.
57. China Food and Drug Administration. 2013 China Drug Review Annual Report. Beijing, China: China Food and Drug Administration; 2014.
58. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS,. Immunotherapy in lung cancer. Transl Lung Cancer Res. 2014; 3: 53-63.